Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CROPSeq_Data]

ABSTRACT: Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CROPSeq_Data]

PROVIDER: PRJNA1010684 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

Project description:Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

| PRJNA1010685 | ENA

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CART]

Project description:Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CART]

| PRJNA1010218 | ENA

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [Pilot_Data]

Project description:Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [Pilot_Data]

| PRJNA1010220 | ENA

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CROPSeq_Data]

Project description:CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced chromosome loss is a universal phenomenon and evaluate its clinical significance, we conducted a systematic analysis in primary human T cells. Arrayed and pooled CRISPR screens revealed that chromosome loss was generalizable across the genome and resulted in partial and entire loss of the chromosome, including in pre-clinical chimeric antigen receptor T cells. T cells with chromosome loss persisted for weeks in culture, implying the potential to interfere with clinical use. A modified cell manufacturing process, employed in our first-in-human clinical trial of Cas9-engineered T cells, dramatically reduced chromosome loss while largely preserving genome editing efficacy. Expression of p53 correlated with protection from chromosome loss observed in this protocol, suggesting both a mechanism and strategy for T cell engineering that mitigates this genotoxicity in the clinic.

2023-11-18 | GSE241882 | GEO

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [Pilot_Data]

2023-11-18 | GSE241839 | GEO

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CART]

2023-11-18 | GSE241838 | GEO

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-11-18 | GSE241683 | GEO

RNA-Guided Human Gene Activation by Cas9/CRISPR-Based Engineered Transcription Factors

Project description:Synthetic transcription factors can be applied in many areas of biotechnology, medicine, and basic research. In contrast to current methods based on engineering new DNA-binding proteins, we show that Cas9 fused to a transcriptional activation domain can be targeted by combinations of guide RNA molecules to induce the expression of endogenous human genes. This simple approach for targeted gene activation circumvents the need for engineering new proteins and will enable widespread synthetic gene regulation. HEK293T cells were transfected with plasmid expressing Cas9-VP64 fusion protein and a guide RNA. As a control, empty guide RNA was transfected. Gene expression was then measured using mRNA-seq, and differential expression calculated using DESeq. All experiments were performed in biological duplicates or triplicates.

2013-07-25 | E-GEOD-47114 | biostudies-arrayexpress

Genetically engineered mouse models of sarcoma using CRISPR/Cas9

Project description:Generation and comparison of CRISPR/Cas9 and Cre-mediated genetically engineered mouse models of sarcoma

| PRJEB22279 | ENA

Allele-specific genome editing using the CRISPR/Cas9 system phenocopies alopecia areata symptomatic patched hair loss in mice

Project description:Using CRISPR/Cas9 for allele-specific genome editing we phenocopied AA symptomatic patched hair loss in mice engineered to carry the Cchcr1 risk allele.

2020-12-31 | GSE100630 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data